Paul Cowan is our Chief Executive Officer and Chairman of our Board of Directors. Mr. Cowan founded us through the acquisition of Alba Bioscience in 2007. He has a broad range of healthcare industry experience gained through over 15 years of employment within industry and investment banking. Previously, Mr. Cowan served as the Chief Financial Officer of Inveresk Research Group, a global contract research organization that was acquired by Charles River Laboratories in 2004. Prior to joining Inveresk in 2001, Mr. Cowan was a senior executive within the Investment Banking department of Bear Stearns & Co., where he led the European biotechnology practice. Prior to Bear Stearns, Mr. Cowan was a senior executive within the Investment Banking department of Morgan Grenfell (acquired by Deutsche Bank in 1990). Mr. Cowan received a Bachelor of Business in accounting from Queensland University of Technology.
Jeremy has over 15 years in healthcare including diagnostics, pharmaceutical and biotechnology. His past experiences include former Commercial Director of Immunohematology, Ortho Clinical Diagnostics, Johnson & Johnson and former Strategy Consultant to healthcare industry with Monitor and McKinsey & Co consultancies.
Ed has 12 years diagnostics experience. Previously he was VP of Manufacturing for Siemens Healthcare Diagnostics where he was the leader of a large reagent plant. Prior to that, he led a site manufacturing and developing point of care instruments and consumables for Siemens. His past experiences include manufacturing, engineering, and logistics roles for Bayer Diagnostics, Ingersoll Rand and Intel.
John has over 30 years experience in diagnostics and extensive knowledge of the global blood bank market. John spent 15 years working in Hospital & Transfusion Service Laboratories in the UK and Middle East, until moving into diagnostic reagent manufacturing in 1990. John was a Board Member at Scottish National Blood Transfusion Service from 1999 until 2007, Chairperson at EDMA Blood Typing Working Party from 1997 until 2007, a member of the EDMA representative to European Commission IVD Expert Group from 2001 until 2007, and a member of the UKBTS Reagents Standing Advisory Committee from 1994 until 2007.
Roland worked for over 20 years as an accounting professional with Andersen, latterly as a partner. Since 2002 he has worked in the healthcare sector initially as Group Financial Controller of Inveresk Research, a NASDAQ listed company and then for approximately six years from 2006 as Chief Financial Officer of Chiltern International, a leading global clinical research organisation. He joined Quotient in 2012 as Chief Financial Officer.